Chemotherapy-Induced Peripheral Neuropathy: Mechanisms and Therapeutic Avenues View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2021-10-21

AUTHORS

Esther H. Bae, Mark K. Greenwald, Ann G. Schwartz

ABSTRACT

Chemotherapy-induced peripheral neuropathy (CIPN) is a serious and often persistent adverse consequence of certain chemotherapeutic agents. It is a major dose-limiting factor of many first-line chemotherapies, affecting 20–50% of patients at standard doses and nearly all patients at high doses. As cancer survivorship continues to increase with improvements in early diagnosis and treatment, more patients will experience CIPN despite completing cancer treatment, which interferes with recovery, leading to chronic pain and worsening quality of life. The National Cancer Institute has identified CIPN as a priority in translational research. To date, there are no FDA-approved drugs for preventing or treating CIPN, with emerging debate on mechanisms and promising new targets. This review highlights current literature and suggests novel approaches to CIPN based on proposed mechanisms of action that aim either to confer neuroprotection against chemotherapy-induced neurotoxicity or reverse the downstream effects of painful neuropathy. More... »

PAGES

2384-2396

References to SciGraph publications

  • 2010-05-25. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA in SUPPORTIVE CARE IN CANCER
  • 2017-02-10. Astragali radix: could it be an adjuvant for oxaliplatin-induced neuropathy? in SCIENTIFIC REPORTS
  • 2020-10-27. Status of peripheral sodium channel blockers for non-addictive pain treatment in NATURE REVIEWS NEUROLOGY
  • 2020-12-14. Cisplatin induced neurotoxicity is mediated by Sarm1 and calpain activation in SCIENTIFIC REPORTS
  • 2019-05-24. Cannabinoids: Current and Future Options to Treat Chronic and Chemotherapy-Induced Neuropathic Pain in DRUGS
  • 2020-12-02. Neurotensin pathway in digestive cancers and clinical applications: an overview in CELL DEATH & DISEASE
  • 2002-01. Chemotherapy-induced peripheral neuropathy in JOURNAL OF NEUROLOGY
  • 2017-08-29. Excessive spinal glutamate transmission is involved in oxaliplatin-induced mechanical allodynia: a possibility for riluzole as a prophylactic drug in SCIENTIFIC REPORTS
  • 2005-08. Agonistic Properties of Cannabidiol at 5-HT1a Receptors in NEUROCHEMICAL RESEARCH
  • 1997-11. Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2019-05-10. Knockdown siRNA Targeting the Mitochondrial Sodium-Calcium Exchanger-1 Inhibits the Protective Effects of Two Cannabinoids Against Acute Paclitaxel Toxicity in JOURNAL OF MOLECULAR NEUROSCIENCE
  • 2020-05-11. Chemotherapy-induced peripheral neuropathy: part 1—current state of knowledge and perspectives for pharmacotherapy in PHARMACOLOGICAL REPORTS
  • 2020-03-09. Programmed axon degeneration: from mouse to mechanism to medicine in NATURE REVIEWS NEUROSCIENCE
  • 2017-09-18. Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial in NEUROTHERAPEUTICS
  • 2015-06-22. Voltage-gated Na+ Channel Activity Increases Colon Cancer Transcriptional Activity and Invasion Via Persistent MAPK Signaling in SCIENTIFIC REPORTS
  • 2019-04-29. Losartan, an Angiotensin II Type 1 Receptor Antagonist, Alleviates Mechanical Hyperalgesia in a Rat Model of Chemotherapy-Induced Neuropathic Pain by Inhibiting Inflammatory Cytokines in the Dorsal Root Ganglia in MOLECULAR NEUROBIOLOGY
  • 2015-02-15. Cancer treatment-related neuropathic pain: proof of concept study with menthol—a TRPM8 agonist in SUPPORTIVE CARE IN CANCER
  • 2009-09-15. Glutamate Carboxypeptidase Inhibition Reduces the Severity of Chemotherapy-Induced Peripheral Neurotoxicity in Rat in NEUROTOXICITY RESEARCH
  • 2019-01-04. High concentration of topical amitriptyline for treating chemotherapy-induced neuropathies in SUPPORTIVE CARE IN CANCER
  • 2007-08. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics in NATURE REVIEWS DRUG DISCOVERY
  • 2006-02-18. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors in NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY
  • 2019-08-13. DF2726A, a new IL-8 signalling inhibitor, is able to counteract chemotherapy-induced neuropathic pain in SCIENTIFIC REPORTS
  • 2017-12-14. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial in SUPPORTIVE CARE IN CANCER
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s13311-021-01142-2

    DOI

    http://dx.doi.org/10.1007/s13311-021-01142-2

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1142048338

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/34676514


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Pain", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Peripheral Nervous System Diseases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Quality of Life", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, 3901 Chrysler Service Drive, Suite 2A, 48201, Detroit, MI, USA", 
              "id": "http://www.grid.ac/institutes/grid.254444.7", 
              "name": [
                "Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, 3901 Chrysler Service Drive, Suite 2A, 48201, Detroit, MI, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Bae", 
            "givenName": "Esther H.", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Karmanos Cancer Institute, Detroit, MI, USA", 
              "id": "http://www.grid.ac/institutes/grid.477517.7", 
              "name": [
                "Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, 3901 Chrysler Service Drive, Suite 2A, 48201, Detroit, MI, USA", 
                "Karmanos Cancer Institute, Detroit, MI, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Greenwald", 
            "givenName": "Mark K.", 
            "id": "sg:person.0716526470.85", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716526470.85"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Karmanos Cancer Institute, Detroit, MI, USA", 
              "id": "http://www.grid.ac/institutes/grid.477517.7", 
              "name": [
                "Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, 3901 Chrysler Service Drive, Suite 2A, 48201, Detroit, MI, USA", 
                "Karmanos Cancer Institute, Detroit, MI, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Schwartz", 
            "givenName": "Ann G.", 
            "id": "sg:person.015310443707.61", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015310443707.61"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s00520-018-4618-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1111097750", 
              "https://doi.org/10.1007/s00520-018-4618-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41583-020-0269-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1125493056", 
              "https://doi.org/10.1038/s41583-020-0269-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41598-019-48231-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1120279890", 
              "https://doi.org/10.1038/s41598-019-48231-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41598-020-78896-w", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1133487492", 
              "https://doi.org/10.1038/s41598-020-78896-w"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00520-010-0911-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018082768", 
              "https://doi.org/10.1007/s00520-010-0911-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s43440-020-00109-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1127518958", 
              "https://doi.org/10.1007/s43440-020-00109-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12035-019-1616-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1113808643", 
              "https://doi.org/10.1007/s12035-019-1616-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41419-020-03245-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1132950735", 
              "https://doi.org/10.1038/s41419-020-03245-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00210-006-0033-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033258093", 
              "https://doi.org/10.1007/s00210-006-0033-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13311-017-0572-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1091835196", 
              "https://doi.org/10.1007/s13311-017-0572-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12031-019-01321-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1114036392", 
              "https://doi.org/10.1007/s12031-019-01321-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11064-005-6978-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036146098", 
              "https://doi.org/10.1007/s11064-005-6978-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/srep42021", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1083739305", 
              "https://doi.org/10.1038/srep42021"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/pl00007853", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1053351904", 
              "https://doi.org/10.1007/pl00007853"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrd2222", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051868416", 
              "https://doi.org/10.1038/nrd2222"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41598-017-08891-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1091313364", 
              "https://doi.org/10.1038/s41598-017-08891-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00520-015-2642-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050667684", 
              "https://doi.org/10.1007/s00520-015-2642-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12640-009-9114-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041695789", 
              "https://doi.org/10.1007/s12640-009-9114-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/srep11541", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033546161", 
              "https://doi.org/10.1038/srep11541"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s40265-019-01132-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1115645597", 
              "https://doi.org/10.1007/s40265-019-01132-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s002800050723", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036685616", 
              "https://doi.org/10.1007/s002800050723"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41582-020-00415-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1132044155", 
              "https://doi.org/10.1038/s41582-020-00415-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00520-017-4013-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1099701868", 
              "https://doi.org/10.1007/s00520-017-4013-0"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2021-10-21", 
        "datePublishedReg": "2021-10-21", 
        "description": "Chemotherapy-induced peripheral neuropathy (CIPN) is a serious and often persistent adverse consequence of certain chemotherapeutic agents. It is a major dose-limiting factor of many first-line chemotherapies, affecting 20\u201350% of patients at standard doses and nearly all patients at high doses. As cancer survivorship continues to increase with improvements in early diagnosis and treatment, more patients will experience CIPN despite completing cancer treatment, which interferes with recovery, leading to chronic pain and worsening quality of life. The National Cancer Institute has identified CIPN as a priority in translational research. To date, there are no FDA-approved drugs for preventing or treating CIPN, with emerging debate on mechanisms and promising new targets. This review highlights current literature and suggests novel approaches to CIPN based on proposed mechanisms of action that aim either to confer neuroprotection against chemotherapy-induced neurotoxicity or reverse the downstream effects of painful neuropathy.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s13311-021-01142-2", 
        "inLanguage": "en", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1294839", 
            "issn": [
              "1933-7213", 
              "1878-7479"
            ], 
            "name": "Neurotherapeutics", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "4", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "18"
          }
        ], 
        "keywords": [
          "chemotherapy-induced peripheral neuropathy", 
          "major dose-limiting factor", 
          "first-line chemotherapy", 
          "chemotherapy-induced neurotoxicity", 
          "dose-limiting factor", 
          "certain chemotherapeutic agents", 
          "quality of life", 
          "National Cancer Institute", 
          "promising new target", 
          "mechanism of action", 
          "painful neuropathy", 
          "peripheral neuropathy", 
          "standard doses", 
          "more patients", 
          "chronic pain", 
          "cancer survivorship", 
          "early diagnosis", 
          "Cancer Institute", 
          "therapeutic avenues", 
          "high doses", 
          "chemotherapeutic agents", 
          "patients", 
          "cancer treatment", 
          "translational research", 
          "new targets", 
          "neuropathy", 
          "adverse consequences", 
          "current literature", 
          "doses", 
          "downstream effects", 
          "treatment", 
          "pain", 
          "neuroprotection", 
          "chemotherapy", 
          "neurotoxicity", 
          "diagnosis", 
          "drugs", 
          "FDA", 
          "mechanism", 
          "review", 
          "agents", 
          "survivorship", 
          "target", 
          "factors", 
          "recovery", 
          "life", 
          "Institute", 
          "action", 
          "date", 
          "effect", 
          "improvement", 
          "novel approach", 
          "literature", 
          "quality", 
          "consequences", 
          "priority", 
          "avenues", 
          "research", 
          "approach", 
          "debate"
        ], 
        "name": "Chemotherapy-Induced Peripheral Neuropathy: Mechanisms and Therapeutic Avenues", 
        "pagination": "2384-2396", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1142048338"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s13311-021-01142-2"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "34676514"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s13311-021-01142-2", 
          "https://app.dimensions.ai/details/publication/pub.1142048338"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-05-20T07:38", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_895.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s13311-021-01142-2"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13311-021-01142-2'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13311-021-01142-2'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13311-021-01142-2'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13311-021-01142-2'


     

    This table displays all metadata directly associated to this object as RDF triples.

    251 TRIPLES      22 PREDICATES      114 URIs      83 LITERALS      12 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s13311-021-01142-2 schema:about N2a5c8db566c94c0fa3baf9f0ea7f04d3
    2 Nc0d1c338c25745a8a5e40a4ca12b6cc4
    3 Nc11013e4c2dd44ebab4ce0c2ed91e546
    4 Nccd89e0f128f45298030fd2cd55c3b67
    5 Ne1e171d4e0574307b9a22558dc3a6037
    6 anzsrc-for:11
    7 anzsrc-for:1112
    8 schema:author N62fa86599ff9488584128ecaf0712455
    9 schema:citation sg:pub.10.1007/pl00007853
    10 sg:pub.10.1007/s00210-006-0033-x
    11 sg:pub.10.1007/s002800050723
    12 sg:pub.10.1007/s00520-010-0911-0
    13 sg:pub.10.1007/s00520-015-2642-8
    14 sg:pub.10.1007/s00520-017-4013-0
    15 sg:pub.10.1007/s00520-018-4618-y
    16 sg:pub.10.1007/s11064-005-6978-1
    17 sg:pub.10.1007/s12031-019-01321-z
    18 sg:pub.10.1007/s12035-019-1616-0
    19 sg:pub.10.1007/s12640-009-9114-1
    20 sg:pub.10.1007/s13311-017-0572-5
    21 sg:pub.10.1007/s40265-019-01132-x
    22 sg:pub.10.1007/s43440-020-00109-y
    23 sg:pub.10.1038/nrd2222
    24 sg:pub.10.1038/s41419-020-03245-8
    25 sg:pub.10.1038/s41582-020-00415-2
    26 sg:pub.10.1038/s41583-020-0269-3
    27 sg:pub.10.1038/s41598-017-08891-1
    28 sg:pub.10.1038/s41598-019-48231-z
    29 sg:pub.10.1038/s41598-020-78896-w
    30 sg:pub.10.1038/srep11541
    31 sg:pub.10.1038/srep42021
    32 schema:datePublished 2021-10-21
    33 schema:datePublishedReg 2021-10-21
    34 schema:description Chemotherapy-induced peripheral neuropathy (CIPN) is a serious and often persistent adverse consequence of certain chemotherapeutic agents. It is a major dose-limiting factor of many first-line chemotherapies, affecting 20–50% of patients at standard doses and nearly all patients at high doses. As cancer survivorship continues to increase with improvements in early diagnosis and treatment, more patients will experience CIPN despite completing cancer treatment, which interferes with recovery, leading to chronic pain and worsening quality of life. The National Cancer Institute has identified CIPN as a priority in translational research. To date, there are no FDA-approved drugs for preventing or treating CIPN, with emerging debate on mechanisms and promising new targets. This review highlights current literature and suggests novel approaches to CIPN based on proposed mechanisms of action that aim either to confer neuroprotection against chemotherapy-induced neurotoxicity or reverse the downstream effects of painful neuropathy.
    35 schema:genre article
    36 schema:inLanguage en
    37 schema:isAccessibleForFree false
    38 schema:isPartOf N6c7caa091a1b48a18c08a5e0a604c9de
    39 N91213462874f403a9e1ad6b1aa0177ea
    40 sg:journal.1294839
    41 schema:keywords Cancer Institute
    42 FDA
    43 Institute
    44 National Cancer Institute
    45 action
    46 adverse consequences
    47 agents
    48 approach
    49 avenues
    50 cancer survivorship
    51 cancer treatment
    52 certain chemotherapeutic agents
    53 chemotherapeutic agents
    54 chemotherapy
    55 chemotherapy-induced neurotoxicity
    56 chemotherapy-induced peripheral neuropathy
    57 chronic pain
    58 consequences
    59 current literature
    60 date
    61 debate
    62 diagnosis
    63 dose-limiting factor
    64 doses
    65 downstream effects
    66 drugs
    67 early diagnosis
    68 effect
    69 factors
    70 first-line chemotherapy
    71 high doses
    72 improvement
    73 life
    74 literature
    75 major dose-limiting factor
    76 mechanism
    77 mechanism of action
    78 more patients
    79 neuropathy
    80 neuroprotection
    81 neurotoxicity
    82 new targets
    83 novel approach
    84 pain
    85 painful neuropathy
    86 patients
    87 peripheral neuropathy
    88 priority
    89 promising new target
    90 quality
    91 quality of life
    92 recovery
    93 research
    94 review
    95 standard doses
    96 survivorship
    97 target
    98 therapeutic avenues
    99 translational research
    100 treatment
    101 schema:name Chemotherapy-Induced Peripheral Neuropathy: Mechanisms and Therapeutic Avenues
    102 schema:pagination 2384-2396
    103 schema:productId Nc1dd66ca53784062b4622cd111e52e7b
    104 Nd7c6d7b8a17c4b949883a28db806d418
    105 Nf3c045db04a1467d8727af1e62ba41f9
    106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1142048338
    107 https://doi.org/10.1007/s13311-021-01142-2
    108 schema:sdDatePublished 2022-05-20T07:38
    109 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    110 schema:sdPublisher N603e69760a2145ad9fbb26b6c410f7db
    111 schema:url https://doi.org/10.1007/s13311-021-01142-2
    112 sgo:license sg:explorer/license/
    113 sgo:sdDataset articles
    114 rdf:type schema:ScholarlyArticle
    115 N2a5c8db566c94c0fa3baf9f0ea7f04d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    116 schema:name Antineoplastic Agents
    117 rdf:type schema:DefinedTerm
    118 N603e69760a2145ad9fbb26b6c410f7db schema:name Springer Nature - SN SciGraph project
    119 rdf:type schema:Organization
    120 N62fa86599ff9488584128ecaf0712455 rdf:first N91da62bfc3c34509896f1fe40d050bda
    121 rdf:rest Na67a748d002c415784117c9b29e19e4c
    122 N6c7caa091a1b48a18c08a5e0a604c9de schema:volumeNumber 18
    123 rdf:type schema:PublicationVolume
    124 N91213462874f403a9e1ad6b1aa0177ea schema:issueNumber 4
    125 rdf:type schema:PublicationIssue
    126 N91da62bfc3c34509896f1fe40d050bda schema:affiliation grid-institutes:grid.254444.7
    127 schema:familyName Bae
    128 schema:givenName Esther H.
    129 rdf:type schema:Person
    130 Na67a748d002c415784117c9b29e19e4c rdf:first sg:person.0716526470.85
    131 rdf:rest Nc3da6e5ef09140839b9f90aaa5a4c456
    132 Nc0d1c338c25745a8a5e40a4ca12b6cc4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    133 schema:name Pain
    134 rdf:type schema:DefinedTerm
    135 Nc11013e4c2dd44ebab4ce0c2ed91e546 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    136 schema:name Quality of Life
    137 rdf:type schema:DefinedTerm
    138 Nc1dd66ca53784062b4622cd111e52e7b schema:name dimensions_id
    139 schema:value pub.1142048338
    140 rdf:type schema:PropertyValue
    141 Nc3da6e5ef09140839b9f90aaa5a4c456 rdf:first sg:person.015310443707.61
    142 rdf:rest rdf:nil
    143 Nccd89e0f128f45298030fd2cd55c3b67 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    144 schema:name Humans
    145 rdf:type schema:DefinedTerm
    146 Nd7c6d7b8a17c4b949883a28db806d418 schema:name doi
    147 schema:value 10.1007/s13311-021-01142-2
    148 rdf:type schema:PropertyValue
    149 Ne1e171d4e0574307b9a22558dc3a6037 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    150 schema:name Peripheral Nervous System Diseases
    151 rdf:type schema:DefinedTerm
    152 Nf3c045db04a1467d8727af1e62ba41f9 schema:name pubmed_id
    153 schema:value 34676514
    154 rdf:type schema:PropertyValue
    155 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    156 schema:name Medical and Health Sciences
    157 rdf:type schema:DefinedTerm
    158 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    159 schema:name Oncology and Carcinogenesis
    160 rdf:type schema:DefinedTerm
    161 sg:journal.1294839 schema:issn 1878-7479
    162 1933-7213
    163 schema:name Neurotherapeutics
    164 schema:publisher Springer Nature
    165 rdf:type schema:Periodical
    166 sg:person.015310443707.61 schema:affiliation grid-institutes:grid.477517.7
    167 schema:familyName Schwartz
    168 schema:givenName Ann G.
    169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015310443707.61
    170 rdf:type schema:Person
    171 sg:person.0716526470.85 schema:affiliation grid-institutes:grid.477517.7
    172 schema:familyName Greenwald
    173 schema:givenName Mark K.
    174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716526470.85
    175 rdf:type schema:Person
    176 sg:pub.10.1007/pl00007853 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053351904
    177 https://doi.org/10.1007/pl00007853
    178 rdf:type schema:CreativeWork
    179 sg:pub.10.1007/s00210-006-0033-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1033258093
    180 https://doi.org/10.1007/s00210-006-0033-x
    181 rdf:type schema:CreativeWork
    182 sg:pub.10.1007/s002800050723 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036685616
    183 https://doi.org/10.1007/s002800050723
    184 rdf:type schema:CreativeWork
    185 sg:pub.10.1007/s00520-010-0911-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018082768
    186 https://doi.org/10.1007/s00520-010-0911-0
    187 rdf:type schema:CreativeWork
    188 sg:pub.10.1007/s00520-015-2642-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050667684
    189 https://doi.org/10.1007/s00520-015-2642-8
    190 rdf:type schema:CreativeWork
    191 sg:pub.10.1007/s00520-017-4013-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099701868
    192 https://doi.org/10.1007/s00520-017-4013-0
    193 rdf:type schema:CreativeWork
    194 sg:pub.10.1007/s00520-018-4618-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1111097750
    195 https://doi.org/10.1007/s00520-018-4618-y
    196 rdf:type schema:CreativeWork
    197 sg:pub.10.1007/s11064-005-6978-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036146098
    198 https://doi.org/10.1007/s11064-005-6978-1
    199 rdf:type schema:CreativeWork
    200 sg:pub.10.1007/s12031-019-01321-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1114036392
    201 https://doi.org/10.1007/s12031-019-01321-z
    202 rdf:type schema:CreativeWork
    203 sg:pub.10.1007/s12035-019-1616-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113808643
    204 https://doi.org/10.1007/s12035-019-1616-0
    205 rdf:type schema:CreativeWork
    206 sg:pub.10.1007/s12640-009-9114-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041695789
    207 https://doi.org/10.1007/s12640-009-9114-1
    208 rdf:type schema:CreativeWork
    209 sg:pub.10.1007/s13311-017-0572-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091835196
    210 https://doi.org/10.1007/s13311-017-0572-5
    211 rdf:type schema:CreativeWork
    212 sg:pub.10.1007/s40265-019-01132-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1115645597
    213 https://doi.org/10.1007/s40265-019-01132-x
    214 rdf:type schema:CreativeWork
    215 sg:pub.10.1007/s43440-020-00109-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1127518958
    216 https://doi.org/10.1007/s43440-020-00109-y
    217 rdf:type schema:CreativeWork
    218 sg:pub.10.1038/nrd2222 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051868416
    219 https://doi.org/10.1038/nrd2222
    220 rdf:type schema:CreativeWork
    221 sg:pub.10.1038/s41419-020-03245-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1132950735
    222 https://doi.org/10.1038/s41419-020-03245-8
    223 rdf:type schema:CreativeWork
    224 sg:pub.10.1038/s41582-020-00415-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1132044155
    225 https://doi.org/10.1038/s41582-020-00415-2
    226 rdf:type schema:CreativeWork
    227 sg:pub.10.1038/s41583-020-0269-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1125493056
    228 https://doi.org/10.1038/s41583-020-0269-3
    229 rdf:type schema:CreativeWork
    230 sg:pub.10.1038/s41598-017-08891-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091313364
    231 https://doi.org/10.1038/s41598-017-08891-1
    232 rdf:type schema:CreativeWork
    233 sg:pub.10.1038/s41598-019-48231-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1120279890
    234 https://doi.org/10.1038/s41598-019-48231-z
    235 rdf:type schema:CreativeWork
    236 sg:pub.10.1038/s41598-020-78896-w schema:sameAs https://app.dimensions.ai/details/publication/pub.1133487492
    237 https://doi.org/10.1038/s41598-020-78896-w
    238 rdf:type schema:CreativeWork
    239 sg:pub.10.1038/srep11541 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033546161
    240 https://doi.org/10.1038/srep11541
    241 rdf:type schema:CreativeWork
    242 sg:pub.10.1038/srep42021 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083739305
    243 https://doi.org/10.1038/srep42021
    244 rdf:type schema:CreativeWork
    245 grid-institutes:grid.254444.7 schema:alternateName Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, 3901 Chrysler Service Drive, Suite 2A, 48201, Detroit, MI, USA
    246 schema:name Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, 3901 Chrysler Service Drive, Suite 2A, 48201, Detroit, MI, USA
    247 rdf:type schema:Organization
    248 grid-institutes:grid.477517.7 schema:alternateName Karmanos Cancer Institute, Detroit, MI, USA
    249 schema:name Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, 3901 Chrysler Service Drive, Suite 2A, 48201, Detroit, MI, USA
    250 Karmanos Cancer Institute, Detroit, MI, USA
    251 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...